fbpx

Type to search

US Imposes Export Restrictions On China Research Institutes

The move closely follows a US investment ban on Chinese facial recognition company SenseTime over its links to Uyghur crackdowns


The flags of the United States and China fly from a lamppost in Boston
China's embassy in Washington said Beijing has worked to implement the Phase 1 agreement "despite the impact of Covid-19, global recession and supply chain disruptions". Photo: Reuters

 

The US Commerce Department has imposed new export restrictions on several Chinese bodies over national security concerns and claims of involvement in the oppression of China’s Uyghurs.

A senior Washington administration official said on Thursday the Commerce Department and Treasury Departments would announce a series of actions targeting Chinese companies that Washington says use biotechnology and surveillance to abuse human rights.

Citing their role in the Chinese government’s alleged oppression of ethnic Uyghurs, the official said the Commerce Department will add China’s Academy of Military Medical Sciences and its 11 research institutes to its list of companies and institutions, restricting access to exports.

 

Also on AF: Asian Stocks Lifted By Fed’s Inflation Battle Plan

 

The move followed a US investment ban placed on Chinese facial recognition company SenseTime, and could worsen already rocky relations between Beijing and Washington.

“These actions come in the broader context of the administration’s efforts to address the misuse of technology to surveil, and in many cases, as with the PRC, to exercise large scale repressive social control,” the senior official told reporters, referring to the People’s Republic of China. 

UN experts and rights groups estimate more than a million people, mainly Uyghurs and members of other Muslim minorities, have been detained in recent years in a vast system of camps in China’s far-west region of Xinjiang. China denies the accusations.

 

  • Reuters with additional editing by Sean O’Meara

 

Read more:

WuXi Biologics Reassures Investors Over US Blacklist

Beijing Slams US Sanctions On Chinese Drug-Making Firms

 

Sean O'Meara

Sean O'Meara is an Editor at Asia Financial. He has been a newspaper man for more than 30 years, working at local, regional and national titles in the UK as a writer, sub-editor, page designer and print editor. A football, cricket and rugby fan, he has a particular interest in sports finance.